We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mechanochemical Ablation Compared to Cyanoacrylate Adhesive

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03392753
Recruitment Status : Completed
First Posted : January 8, 2018
Results First Posted : December 7, 2021
Last Update Posted : August 4, 2022
Sponsor:
Collaborator:
Singapore General Hospital
Information provided by (Responsible Party):
Imperial College London

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This study will be comparing the treatment of varicose veins using either mechanochemical ablation (MOCA) or cyanoacrylate adhesive (CAE). Patients will be randomised to receiving either MOCA or CAE.

The pain scores, clinical scores, quality of life scores, occlusion and re-intervention rate at 2 weeks, 3, 6 and 12 months as well as the cost effectiveness of each intervention will be assessed.


Condition or disease Intervention/treatment Phase
Varicose Veins Procedure: Mechanochemical ablation Procedure: Cyanoacrylate adhesive Not Applicable

Detailed Description:

This will be a randomised clinical trial comparing MOCA to CAE. Patients will be randomised into group A (MOCA) or group B (CAE). Only the endovenous ablation part of the procedure will be randomised while the decision as to whether patients should receive treatment of their varicose tributaries will be at the discretion of the clinical team.

The device used for MOCA (group A) will be the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).

The device used for CAE (group B) will be the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).

Re-intervention of the treated saphenous veins will not be decided until at least 3 months after their initial procedure.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 167 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking Description: An internet-based randomisation service will be used Outcome assessors will be blinded as to treatment offered
Primary Purpose: Treatment
Official Title: Randomised Controlled Trial of Mechanochemical Ablation Versus Cyanoacrylate Adhesive for the Treatment of Varicose Veins
Actual Study Start Date : November 6, 2017
Actual Primary Completion Date : July 31, 2019
Actual Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Varicose Veins

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Mechanochemical ablation (MOCA)
Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
 Procedure: Mechanochemical ablation
Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)
Active Comparator: Cyanoacrylate adhesive (CAE)
Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
 Procedure: Cyanoacrylate adhesive
Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Pain Score During Ablation [ Time Frame: On day 0 immediately following vein ablation ]
    Pain score during saphenous vein ablation using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)


Secondary Outcome Measures :
  1. Pain Score at the End of the Procedure [ Time Frame: On day 0 following vein ablation and any tributary treatment ]
    Pain score at the end of the procedure using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)

  2. Generic Quality of Life as Per EQ-5D Questionnaire [ Time Frame: Recorded at 12 months ]
    Using the EuroQoL's EQ-5D questionnaire (-0.085=worse quality of life; 1.000=best quality of life)

  3. Disease Specific Quality of Life as Per the AVVQ [ Time Frame: Recorded at 12 months ]
    Using the Aberdeen Varicose Vein Questionnaire (AVVQ) questionnaire (0=best quality of life; 100=worse quality of life)

  4. Disease Specific Quality of Life as Per the CIVIQ-20 [ Time Frame: 12 months ]
    Using the CIVIQ-20 questionnaire (0=best quality of life; 100=worse quality of life)

  5. Clinical Change as Per VCSS [ Time Frame: 12 months ]
    Using the Venous Clinical Severity Score (VCSS) (0=best; 30=worse)

  6. Pain Score Over the First 10 Days [ Time Frame: For the first 10 days since procedure ]
    Pain score over the first 10 days using a 0-100mm visual analogue scale (0=no pain; 100=worst pain). The mean pain score was recorded daily and a mean value was calculated.

  7. Degree of Bruising at 2 Weeks [ Time Frame: 2 weeks ]
    Degree of bruising at 2 weeks using a categorical 0-5 bruising scale (0=no bruising; 5=bruising extending beyond treated segment). The outcome measured is the number of participants with a degree of bruising between category 0-1.

  8. Time to Return to Normal Activities [ Time Frame: 2 weeks ]
    Length of time in days until normal activities are resumed

  9. Occlusion Rates [ Time Frame: 12 months ]
    Rate of occlusion as assessed by duplex ultrasound


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults over 18 years of age
  • Symptomatic GSV or SSV vein reflux > 0.5 seconds on colour Duplex

Exclusion Criteria:

  • Current DVT
  • Recurrent varicose veins
  • Arterial disease (ABPI<0.8)
  • Vein diameter < 3mm
  • Patient who are unwilling to participate
  • Inability or unwillingness to complete questionnaires
  • Adverse reaction to sclerosant or cyanoacrylate
  • Not been involved in another venous trial for at least 6 months
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03392753


Locations
Layout table for location information
United Kingdom
Charing Cross Hospital, Imperial College London
London, United Kingdom, W6 8RF
Sponsors and Collaborators
Imperial College London
Singapore General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Alun H Davies Imperial College London
  Study Documents (Full-Text)

Documents provided by Imperial College London:
Study Protocol  [PDF] November 21, 2018
Statistical Analysis Plan  [PDF] November 21, 2018

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT03392753    
Other Study ID Numbers: 17/LO/1457
First Posted: January 8, 2018    Key Record Dates
Results First Posted: December 7, 2021
Last Update Posted: August 4, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Varicose Veins
Vascular Diseases
Cardiovascular Diseases